Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 4:09 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
Slide #19. Emergent BioSolutions Inc. — Cangene Corporation
| Acquirer: |
Emergent BioSolutions Inc. (EBS) |
| Acquiree: |
Cangene Corporation (CNJ.CA) |
| Details: |
Cangene Corporation ("Cangene") (TSX: CNJ) today announced that the Ontario Superior Court of Justice issued a final order approving the Plan of Arrangement for the previously announced acquisition of Cangene by Emergent BioSolutions Inc. (NYSE: EBS). Under the court-approved Plan of Arrangement, Cangene shareholders will receive US$3.24 per share (C$3.561 per share) in cash, for an aggregate purchase price of US$222 million (approximately C$244 million2). |
Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).
EBS SEC Filing Email Alerts Service
Open the EBS Page at The Online Investor »
Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).
EBS SEC Filing Email Alerts Service
Open the CNJ.CA Page at The Online Investor »
| Company Name: |
| Emergent BioSolutions Inc |
| Stock buyback: |
| EBS buyback |
| Website: |
| www.emergentbiosolutions.com |
| Sector: |
| Biotechnology |
| Number of ETFs Holding EBS: |
| 62 |
| Total Market Value Held by ETFs: |
| $661.39M |
| Total Market Capitalization: |
| $3.97B |
| % of Market Cap. Held by ETFs: |
| 16.66% |
|
Quotes delayed 20 minutes
|
